Will Bluejay Diagnostics stock go up?

According to Danelfin AI, Bluejay Diagnostics has today an AI Score of 1/10 (Strong Sell rating), because its probability of beating the market in 3 months (37.56%) is -13.26% vs. the average probability (50.82%) of all US-listed stocks.

What is the target price for Bluejay Diagnostics stock?

The Bluejay Diagnostics target price is $1.16 (1Y), according to the average price target offered by analysts.

Is it a good time to buy, sell, or hold Bluejay Diagnostics stock right now?

Bluejay Diagnostics has today a Strong Sell rating (AI Score 1/10), according to Danelfin AI. Its probability of beating the market in 3 months (37.56%) is -13.26% vs. the average probability (50.82%) of all US-listed stocks, based on our AI-powered analysis. You can find more details on whether Bluejay Diagnostics stock is a good buy .

Is Bluejay Diagnostics undervalued right now?

Based on analysts, the average price target downside for Bluejay Diagnostics is 0.00% (1Y). According to Danelfin AI, Bluejay Diagnostics has today an AI Score of 1/10 (Strong Sell Rating).

What was the price range of Bluejay Diagnostics stock over the past 12 months?

The Bluejay Diagnostics stock price range over the past 12 months has been $1.16 - $14.

What is going on with Bluejay Diagnostics stock in the last 3 months?

The Bluejay Diagnostics stock performance in the last quarter has been -38.62%.

Does Bluejay Diagnostics offer dividend payments?

No, Bluejay Diagnostics does not currently pay dividends.

What is the current market capitalization of Bluejay Diagnostics?

Bluejay Diagnostics's market cap is $1.18M, as of 2026-07-03 08:00.

Bluejay Diagnostics Inc (BJDX) AI Stock Analysis

Advanced Chart

Custom range

Jul 3, 2025

→

Jul 3, 2026

Custom range

Jul 3, 2025

→

Jul 3, 2026

BJDX AI-Powered Stock Analysis

AI Score Explanation

Generating AI Score explanation

We're getting the explanation ready so you can easily understand what's behind the AI Score. This may take a few seconds.

AI Score Explanation

Generating AI Score explanation

We're getting the explanation ready so you can easily understand what's behind the AI Score. This may take a few seconds.

Valuation+0.51%
How the stock is priced relative to its fundamentals

Sentiment-5.30%
How analysts and the market view the stock
Momentum-3.86%
Direction and strength of recent price movements
Volatility-2.19%
How much the stock price tends to fluctuate
Size & Liquidity-1.18%
Company size and trading liquidity
Growth-0.89%
Expected pace of revenue and earnings expansion
Financial Strength-0.35%
Balance sheet strength and financial resilience

BJDX probability advantage of beating the market (3M):

-13.26%

AI Score

Strong Sell

Bluejay Diagnostics (BJDX) has an AI Score of 1/10 (Strong Sell) because, according to an overall analysis, it has a probability advantage of -13.26% of beating the market (S&P500) in the next 3 months. This advantage is calculated as the difference between the average probability of any US-listed stock (50.82%) and the probability of BJDX (37.56%) of outperforming the market in the next 3 months, as determined by Danelfin AI’s comprehensive analysis.

Average probability of any US-listed stock of beating the market (3M)50.82%
BJDX probability advantage of beating the market (3M)-13.26%
BJDX probability of beating the market (3M)37.56%

BJDX probability advantage of beating the market (3M): -13.26%

The AI-powered overall analysis of Bluejay Diagnostics (BJDX) is based on the 27 fundamental, technical, and sentiment features that had the greatest impact on stock performance during the last 12 months (alpha signals). These alpha signals explain the probability advantage of BJDX:

Type	Alpha Signal	Current Value	Value Decile Position	Probability Advantage Impact (3M)
Technical	Chart Pattern (504d)	figure_41	N/A	-1.95%
Sentiment	Industry (GICS)	Health Care Equipment & Supplies	N/A	-1.90%
Fundamental	Fundamentals Impact (Long Tail)	-	N/A	+1.69%
Sentiment	Fear & Greed Index (CNN)	31	N/A	-1.22%
Technical	Maximum Volatility	22.83%		-1.13%
Technical	ATR (180d Volatility)	67.7		-1.08%
Sentiment	Institutional Ownership	5.69%		-1.04%
Fundamental	Basic EPS Consolidated	-1.95	N/A	-0.89%
Technical	Chart Pattern (252d)	figure_32	N/A	+0.81%
Technical	Chart Pattern (120d)	figure_148	N/A	-0.77%
Fundamental	Upgrade to unlock			-0.77%
Sentiment	Upgrade to unlock			-0.76%
Fundamental	Upgrade to unlock			-0.61%
Technical	Upgrade to unlock			-0.58%
Fundamental	Upgrade to unlock			-0.56%

Rest of Alpha Signals: -2.49%

BJDX probability advantage of beating the market (3M)Total:-13.26%
BJDX AI Score

Significant changes Vs previous day

BJDX Short Trading Parameters

These suggested trading parameters for a 3-month horizon help improve risk management and decision-making.

Entry:$1.16
Horizon: 3 months
Stop Loss:$XXXXXPro (XXXXXPro)
Take Profit:$XXXXXPro (XXXXX
Pro
)

BJDX Proven Sell Signal & Price Forecast

This is the price chart for BJDX from January 2, 2026 until today. The chart indicates, in red, the 113 days when the stock received a Sell/Strong Sell rating (sell signals, AI Score 1 to 3).

Forecast: In the section below, the central dotted line represents the most expected path, while the shaded area indicates the anticipated price range. This is based on previous Sell signals with a 90% confidence level.

Full Track Record

Unlock AI-powered forecast

Closing price (USD)
Sell signals

Forecast:

1 Month
3 Months
6 Months
1 Year

BJDX Average Past Performance & Loss Rate

Three months after its 1106 Sell signals since July 2026, BJDX had an average performance of xxxxxxx and a xxxxxx Loss rate (negative performance).

1106 Past BJDX Sell Signals	1 Month Later	3 Months Later	6 Months Later	1 Year Later
Average Performance				-83.70%
Average Alpha				-97.55%
Loss Rate (% Negative Perf.)				100.00%
% Negative Alpha				100.00%

BJDX Frequently Asked Questions

Will Bluejay Diagnostics stock go up?
According to Danelfin AI, Bluejay Diagnostics has today an AI Score of 1/10 (Strong Sell rating), because its probability of beating the market in 3 months (37.56%) is -13.26% vs. the average probability (50.82%) of all US-listed stocks.
What is the target price for Bluejay Diagnostics stock?
Is it a good time to buy, sell, or hold Bluejay Diagnostics stock right now?
Is Bluejay Diagnostics undervalued right now?
What was the price range of Bluejay Diagnostics stock over the past 12 months?
What is going on with Bluejay Diagnostics stock in the last 3 months?
Does Bluejay Diagnostics offer dividend payments?
What is the current market capitalization of Bluejay Diagnostics?

Bluejay Diagnostics Inc Company Profile

In the realm of medical diagnostics, Bluejay Diagnostics, Inc. holds a prominent position, investing its resources in the creation of rapid disease progression tests within the U.S healthcare scene. At its core sits Symphony platform, a revolutionary technology comprising synergistic components: Symphony analyzer and Symphony Cartridge. Using non-contact centrifugal force, the Analyzer oversees an intricate dance of blood processing, biomarker isolation, and immunoassay preparation. In contrast, the precisely prepared reagents and multiple components present in the cartridge ensures smooth performance.

Another notable innovation from Bluejay is ALLEREYE. This point-of-care device has been designed to diagnose allergic conjunctivitis accurately with remarkable ease, highlighting Bluejay's commitment to patient-centered solutions.

Never one to rest on its laurels, Bluejay broadens its suite of offerings by developing a test named IL-6 that monitors disease progression in critical care scenarios – emphasizing their priority for constant innovation in the testing arena.

Additionally, two other noteworthy developments from Bluejay include hsTNT/I and NT-proBNP. These diagnostic tools have been specially tailored to assess chest pain severity in patients - further demonstrating their mission of comprehensive patient care.

Founded in 2015, this Massachusetts-based firm has anchored itself in Acton since inception - where it continues to explore and deliver top-tier diagnostic solutions nationwide.

Sector:
Country:United States
Industry:
Address:360 Massachusetts Avenue, Suite 203, Acton
Employees:6
Website:bluejaydx.com

Pros

High switching costs for integrated diagnostic platforms

Proprietary intellectual property in diagnostic assays

Addressing unmet diagnostic needs in specific disease areas

Scalable manufacturing potential for disposable test cartridges

Regulatory barriers to entry for new diagnostic devices

Cons

Extensive regulatory approval timelines for medical devices

Reimbursement uncertainty for novel diagnostic tests

High capital expenditure for research and development

Risk of technology obsolescence in diagnostics market

Customer concentration among large healthcare networks

Company	AI Score	Compare
BDSXBiodesix Inc
TRIBTrinity Biotech PLC
QDELQuidelOrtho Corp
DGXQuest Diagnostics Inc
CSTLCastle Biosciences Inc

Company	AI Score	Compare
BDSXBiodesix Inc
TRIBTrinity Biotech PLC
QDELQuidelOrtho Corp
DGXQuest Diagnostics Inc
CSTLCastle Biosciences Inc

BJDX Stock AI Analysis High Risk